JG
APLS

Jefferies Group’s Apellis Pharmaceuticals APLS Stock Holding History

Jefferies Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-349,000
Closed -$11.5M – 1613
2021
Q3 		$11.5M Buy
349,000
+289,400
+486% +$16.3M 0.08% 221
2021
Q2 		$3.77M Buy
+59,600
New +$3.08M 0.02% 548

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Jefferies Group's APLS Position: Q3 2022 in Review

Jefferies Group sold out of Apellis Pharmaceuticals (APLS) in Q3 2022, closing a stake of 11,214 shares — an estimated $507K sold.

Jefferies Group first reported a position in APLS in Q3 2019 and held it in 8 quarters. The position peaked at $32.2M in Q2 2021. 250 funds tracked by Wall St. Rank hold APLS as of Q3 2022.

  • Jefferies Group reported no remaining Apellis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Jefferies Group sold 11,214 Apellis Pharmaceuticals shares in Q3 2022, an estimated $507K.
  • Jefferies Group first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 8 quarters.
  • Jefferies Group's Apellis Pharmaceuticals position peaked at $32.2M in Q2 2021.
  • 250 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.